Researchers in Basel and Cambridge have engineered small molecules known as Phagocytic Synapse Enhancers (PSEs) that bridge the gap between stubborn solid tumors and immune system macrophages. Published in the journal Cancer Research, this approach forces cold tumors to drop their immunological shields by reprogramming myeloid cells to devour cancer cells and degrade suppressive PD-L1 signals.
Understanding Cold Tumors and the Myeloid Challenge
Solid tumors frequently develop defensive microenvironments that exclude or disarm standard immune defenses, earning them the clinical label of “cold tumors.” While modern immunotherapies focus heavily on T-cells, most solid tumors are dominated by myeloid cells, specifically macrophages. In these environments, cancer cells hijack macrophages by expressing the surface protein programmed death-ligand 1 (PD-L1), a molecular brake that acts as a stop signal for the immune system.
As Professor Dr. Gonçalo Bernardes of the University of Cambridge noted, myeloid cells have been a missing piece in immunotherapy design. Rather than fighting the tumor, these macrophages are subverted into protective guards. To counteract this evasion mechanism, collaborative teams across Switzerland and the United Kingdom set out to build a molecular bridge that flips these resident cells from tumor-friendly to tumor-hostile.
The Mechanism of Action: Phagocytic Synapse Enhancers
The newly developed PSE molecules feature a dual-functional design. One end of the engineered molecule specifically binds to the PD-L1 proteins expressed in the tumor microenvironment, while the other end carries Tuftsin, a molecule that docks with macrophage receptors to trigger cellular activation. By tethering the macrophage directly to the cancer cell, the PSE functions as an active physical connector that commands the macrophage to engulf and digest the tumor cell.
Beyond acting as a physical tether, the PSE treatment forces macrophages to internalize and clear PD-L1 from their own surfaces. This dual action simultaneously removes the inhibitory stop signals facing T-cells and unleashes targeted phagocytosis—the cellular process by which immune cells engulf and destroy pathogens or abnormal tissue. Lead author Dr. Valerio Sabatino conducted the underlying studies across institutions supported by a Postdoc-Mobility-Grant from the Swiss National Science Foundation.
In Plain English: The Clinical Takeaway
- Targeting the Microenvironment: The therapy alters the tissue surrounding solid tumors, shifting it from protecting the cancer to attacking it.
- Cellular Re-education: Instead of focusing solely on T-cells, the treatment reprograms abundant macrophage immune cells to actively consume tumor cells.
- Bypassing Checkpoint Resistance: By latching onto PD-L1 molecules, the PSE design strips away the stop signals that usually paralyze immune responses.
Pre-Clinical Validation Models and Therapeutic Scope
The research teams tested the efficacy of PSE molecules across multiple laboratory environments, including cellular cultures, zebrafish models, and murine (mouse) models representing various solid tumor types. These pre-clinical assessments demonstrated that molecular bridging can successfully overcome local immunosuppression.
According to Professor Dr. Gregor Hutter of the University of Basel and the University Hospital Basel, this strategy addresses a core limitation of current oncology pipelines. Because solid tumors actively recruit myeloid cells into their service, turning those very cells against the malignancy provides a distinct pharmacological advantage.
| Feature | Biological Function |
|---|---|
| Target Receptor | PD-L1 expressed on tumor and macrophage surfaces |
| Activating Peptide | Tuftsin, which binds and activates macrophage receptors |
| Primary Mechanism | Physical bridging (synapse) promoting phagocytosis and PD-L1 degradation |
| Tested Models | In vitro cell cultures, zebrafish, and murine models |
Contraindications & When to Consult a Doctor
Because Phagocytic Synapse Enhancers are currently undergoing pre-clinical evaluation in laboratory and animal models, they are not available for clinical use, and no human dosing guidelines exist. Patients undergoing active cancer therapies should strictly follow their oncology care teams’ regimens. Anyone experiencing persistent, unexplained constitutional symptoms—such as sudden weight loss, persistent fatigue, localized swelling, or changes in lymph node size—should consult a primary care physician or qualified oncologist immediately for diagnostic evaluation.
Future Trajectory in Immuno-Oncology
The validation of PSE molecules in animal models marks a shift in how translational immunologists view the tumor microenvironment. By transforming macrophages from passive bystanders into active tumor destroyers, this class of molecules offers a foundation for future combination therapies.
References
- Sabatino, V., et al. (2026). Cancer Research.
